References
- Pauls DL. The genetics of obsessive-compulsive disorder: a review. Dialogues Clin Neurosci. 2010;12(2):149–163. doi:10.1002/ajmg.c.3016820623920
- Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry. 2010;15(1):53–63. doi:10.1038/mp.2008.9418725912
- Guo X, Meng Z, Huang G, et al. Meta-analysis of the prevalence of anxiety disorders in mainland China from 2000 to 2015. Sci Rep. 2016;6:28033. doi:10.1038/srep2803327306280
- Lochner C, Mogotsi M, Du Toit PL, Kaminer D, Niehaus DJ, Stein DJ. Quality of life in anxiety disorders: a comparison of obsessive-compulsive disorder, social anxiety disorder, and panic disorder. Psychopathology. 2003;36(5):255–262. doi:10.1159/00007345114571055
- Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005;162(6):1171–1178. doi:10.1176/appi.ajp.162.6.117115930066
- Huppert JD, Simpson HB, Nissenson KJ, Liebowitz MR, Foa EB. Quality of life and functional impairment in obsessive-compulsive disorder: a comparison of patients with and without comorbidity, patients in remission, and healthy controls. Depress Anxiety. 2009;26(1):39–45. doi:10.1002/da.2050618800368
- Geller DA, Biederman J, Stewart SE, et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry. 2003;160(11):1919–1928. doi:10.1176/appi.ajp.160.11.191914594734
- Skapinakis P, Caldwell D, Hollingworth W, et al. A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults. Health Technol Assess. 2016;20(43):1–392. doi:10.3310/hta20430
- Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2010;15(8):850–855. doi:10.1038/mp.2009.5019468281
- Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683–1696. doi:10.1001/jama.297.15.168317440145
- Soomro GM, Altman DG, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765. doi:10.1002/14651858.CD00176518253995
- Brunoni AR, Valiengo L, Baccaro A, et al. The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry. 2013;70(4):383–391. doi:10.1001/2013.jamapsychiatry.3223389323
- Guo Q, Li C, Wang J. Updated review on the clinical use of repetitive transcranial magnetic stimulation in psychiatric disorders. Neurosci Bull. 2017;33(6):747–756. doi:10.1007/s12264-017-0185-329064064
- Martin DM, McClintock SM, Forster JJ, Lo TY, Loo CK. Cognitive enhancing effects of rTMS administered to the prefrontal cortex in patients with depression: a systematic review and meta-analysis of individual task effects. Depress Anxiety. 2017;34(11):1029–1039. doi:10.1002/da.2265828543994
- Zhou DD, Wang W, Wang GM, Li DQ, Kuang L. An updated meta-analysis: short-term therapeutic effects of repeated transcranial magnetic stimulation in treating obsessive-compulsive disorder. J Affect Disord. 2017;215:187–196. doi:10.1016/j.jad.2017.03.03328340445
- Berlim MT, Neufeld NH, Van Den Eynde F. Repetitive transcranial magnetic stimulation (rTMS) for obsessive-compulsive disorder (OCD): an exploratory meta-analysis of randomized and sham-controlled trials. J Psychiatr Res. 2013;47(8):999–1006. doi:10.1016/j.jpsychires.2013.03.02223615189
- Ma ZR, Shi LJ. Repetitive transcranial magnetic stimulation (rTMS) augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant obsessive-compulsive disorder (OCD): a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2014;7(12):4897–4905.25663986
- Trevizol AP, Shiozawa P, Cook IA, et al. Transcranial magnetic stimulation for obsessive-compulsive disorder: an updated systematic review and meta-analysis. J Ect. 2016;32(4):262–266. doi:10.1097/YCT.000000000000033527327557
- Rehn S, Eslick GD, Brakoulias V. A meta-analysis of the effectiveness of different cortical targets used in repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Obsessive-Compulsive Disorder (OCD). Psychiatr Q. 2018;89(3):645–665. doi:10.1007/s11126-018-9566-729423665
- Schürks M, Rist PM, Kurth T. 5-HTTLPR polymorphism in the serotonin transporter gene and migraine: a systematic review and meta-analysis. Cephalalgia. 2010;30(11):1296–1305. doi:10.1177/033310241036292920959425
- Provenzi L, Giorda R, Beri S, Montirosso R. SLC6A4 methylation as an epigenetic marker of life adversity exposures in humans: a systematic review of literature. Neurosci Biobehav Rev. 2016;71:7–20. doi:10.1016/j.neubiorev.2016.08.02127565518
- Taylor S. Disorder-specific genetic factors in obsessive-compulsive disorder: a comprehensive meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2016;171B(3):325–332. doi:10.1002/ajmg.b.3240726616111
- Mak L, Streiner DL, Steiner M. Is serotonin transporter polymorphism (5-HTTLPR) allele status a predictor for obsessive-compulsive disorder? A meta-analysis. Arch Womens Ment Health. 2015;18(3):435–445. doi:10.1007/s00737-015-0526-z25896187
- Sinopoli VM, Burton CL, Kronenberg S, Arnold PD. A review of the role of serotonin system genes in obsessive-compulsive disorder. Neurosci Biobehav Rev. 2017;80:372–381. doi:10.1016/j.neubiorev.2017.05.02928576508
- Zhang K, Cao L, Zhu W, et al. Association between the efficacy of fluoxetine treatment in obsessive-compulsive disorder patients and SLC1A1 in a Han Chinese population. Psychiatry Res. 2015;229(1–2):631–632. doi:10.1016/j.psychres.2015.06.03926154820
- Zheng Y, Zhao J, Phillips M, et al. Validity and reliability of the Chinese Hamilton depression rating scale. Br J Psychiatry. 1988;152:660–664.3167442
- Pallanti S, Hollander E, Bienstock C, et al. Treatment non-response in OCD: methodological issue and operational definitions. Int J Neuropsychopharmacol. 2002;5(2):181–191. doi:10.1017/S146114570200290012135542
- Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24(8):1011–1030. doi:10.1016/j.cpr.2004.08.00415533282
- Zaman R, Robbins TW. Is there potential for repetitive Transcranial Magnetic Stimulation (rTMS) as a treatment of OCD? Psychiatr Danub. 2017;29(Suppl 3):672–678.28953851
- Norman LJ, Carlisi C, Lukito S, et al. Structural and functional brain abnormalities in attention-deficit/hyperactivity disorder and obsessive-compulsive disorder: a comparative meta-analysis. JAMA Psychiatry. 2016;73(8):815–825. doi:10.1001/jamapsychiatry.2016.070027276220
- Abramovitch A, Abramowitz JS, Mittelman A, Stark A, Ramsey K, Geller DA. Research review: neuropsychological test performance in pediatric obsessive-compulsive disorder-a meta-analysis. J Child Psychol Psychiatry. 2015;56(8):837–847. doi:10.1111/jcpp.1241425866081
- Purcell R, Maruff P, Kyrios M, Pantelis C. Neuropsychological deficits in obsessive-compulsive disorder: a comparison with unipolar depression, panic disorder, and normal controls. Arch Gen Psychiatry. 1998;55(5):415–423.9596044
- Rao NP, Reddy YCJ, Kumar KJ, Kandavel T, Chandrashekar CR. Are neuropsychological deficits trait markers in OCD? Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1574–1579. doi:10.1016/j.pnpbp.2008.05.02618582524
- Mantovani A, Rossi S, Bassi BD, Simpson HB, Fallon BA, Lisanby SH. Modulation of motor cortex excitability in obsessive-compulsive disorder: an exploratory study on the relations of neurophysiology measures with clinical outcome. Psychiatry Res. 2013;210(3):1026–1032. doi:10.1016/j.psychres.2013.08.05424064461
- Haber SN, Heilbronner SR. Translational research in OCD: circuitry and mechanisms. Neuropsychopharmacology. 2013;38(1):252–253. doi:10.1038/npp.2012.18223147494
- Bari A, Robbins TW. Inhibition and impulsivity: behavioral and neural basis of response control. Prog Neurobiol. 2013;108:44–79. doi:10.1016/j.pneurobio.2013.06.00523856628
- de Wit SJ, de Vries FE, van der Werf YD, et al. Presupplementary motor area hyperactivity during response inhibition: a candidate endophenotype of obsessive-compulsive disorder. Am J Psychiatry. 2012;169(10):1100–1108. doi:10.1176/appi.ajp.2012.1201007323032388
- Hawken E, Dilkov D, Kaludiev E, Simek S, Zhang F, Milev R. Transcranial magnetic stimulation of the supplementary motor area in the treatment of obsessive-compulsive disorder: a multi-site study. Int J Mol Sci. 2016;17:420. doi:10.3390/ijms1703042027011177
- Lin PY. Meta-analysis of the association of serotonin transporter gene polymorphism with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):683–689. doi:10.1016/j.pnpbp.2006.12.02417291658
- Bloch MH, Landeros-Weisenberger A, Sen S, et al. Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(6):850–858. doi:10.1002/ajmg.b.3069918186076
- Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003;301(5631):386–389. doi:10.1126/science.108396812869766
- Risch N, Herrell R, Lehner T, et al. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA. 2009;301(23):2462–2471. doi:10.1001/jama.2009.87819531786
- Karg K, Burmeister M, Shedden K, Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry. 2011;68(5):444–454. doi:10.1001/archgenpsychiatry.2010.18921199959
- Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L. Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J. 2002;2(3):176–181. doi:10.1038/sj.tpj.650009012082589
- Bocchio-Chiavetto L, Miniussi C, Zanardini R, et al. 5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neurosci Lett. 2008;437(2):130–134. doi:10.1016/j.neulet.2008.04.00518450378